Exagen (XGN) Enterprise Value (2018 - 2026)

Exagen has reported Enterprise Value for 9 years, with the latest figure at -$21.5 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 92.18% year-over-year to -$21.5 million; the trailing twelve-month figure through Mar 2026 stood at -$21.5 million (down 92.18% YoY), and the FY2025 full-year result was -$32.2 million, down 46.22% from the prior year.
• Enterprise Value for Q1 2026 stood at -$21.5 million, up from -$32.2 million in the prior quarter.
• The five-year high for Enterprise Value was -$11.2 million in Q1 2025, with the low at -$89.8 million in Q1 2022.
• Historically, Enterprise Value has averaged -$39.5 million across 5 years, with a median of -$31.5 million in 2023.
• Annual changes were most pronounced in 2025 — Enterprise Value jumped 59.0% — and 2026, when it sank 92.18%.
• Exagen's Enterprise Value stood at -$62.4 million in 2022, then soared by 41.51% to -$36.5 million in 2023, then soared by 39.62% to -$22.0 million in 2024, then plunged by 46.22% to -$32.2 million in 2025, then jumped by 33.23% to -$21.5 million in 2026.
• The last three Enterprise Value figures came in at -$21.5 million (Q1 2026), -$32.2 million (Q4 2025), and -$35.7 million (Q3 2025), per Business Quant data.